BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 33323237)

  • 21. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.
    Aronson R; Li A; Brown RE; McGaugh S; Riddell MC
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advanced hybrid closed loop therapy versus conventional treatment in adults with type 1 diabetes (ADAPT): a randomised controlled study.
    Choudhary P; Kolassa R; Keuthage W; Kroeger J; Thivolet C; Evans M; Ré R; de Portu S; Vorrink L; Shin J; Habteab A; Castañeda J; da Silva J; Cohen O;
    Lancet Diabetes Endocrinol; 2022 Oct; 10(10):720-731. PubMed ID: 36058207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    Ware J; Allen JM; Boughton CK; Wilinska ME; Hartnell S; Thankamony A; de Beaufort C; Schierloh U; Fröhlich-Reiterer E; Mader JK; Kapellen TM; Rami-Merhar B; Tauschmann M; Nagl K; Hofer SE; Campbell FM; Yong J; Hood KK; Lawton J; Roze S; Sibayan J; Bocchino LE; Kollman C; Hovorka R;
    N Engl J Med; 2022 Jan; 386(3):209-219. PubMed ID: 35045227
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unsupervised home use of an overnight closed-loop system over 3-4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes.
    Thabit H; Elleri D; Leelarathna L; Allen JM; Lubina-Solomon A; Stadler M; Walkinshaw E; Iqbal A; Choudhary P; Wilinska ME; Barnard KD; Heller SR; Amiel SA; Evans ML; Dunger DB; Hovorka R
    Diabetes Obes Metab; 2015 May; 17(5):452-8. PubMed ID: 25492378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAP02 study): an open-label, multicentre, multinational, randomised cross-over study protocol.
    Fuchs J; Allen JM; Boughton CK; Wilinska ME; Thankamony A; de Beaufort C; Campbell F; Yong J; Froehlich-Reiterer E; Mader JK; Hofer SE; Kapellen TM; Rami-Merhar B; Tauschmann M; Hood K; Kimbell B; Lawton J; Roze S; Sibayan J; Cohen N; Hovorka R;
    BMJ Open; 2021 Feb; 11(2):e042790. PubMed ID: 33579766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.
    Hovorka R; Kumareswaran K; Harris J; Allen JM; Elleri D; Xing D; Kollman C; Nodale M; Murphy HR; Dunger DB; Amiel SA; Heller SR; Wilinska ME; Evans ML
    BMJ; 2011 Apr; 342():d1855. PubMed ID: 21493665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CamAPS FX Hybrid Closed-Loop with Ultra-Rapid Lispro Compared with Standard Lispro in Adults with Type 1 Diabetes: A Double-Blind, Randomized, Crossover Study.
    Nwokolo M; Lakshman R; Hartnell S; Alwan H; Ware J; Allen JM; Wilinska ME; Evans ML; Hovorka R; Boughton CK
    Diabetes Technol Ther; 2023 Dec; 25(12):856-863. PubMed ID: 37823892
    [No Abstract]   [Full Text] [Related]  

  • 30. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
    Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
    Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Home Use of an Artificial Beta Cell in Type 1 Diabetes.
    Thabit H; Tauschmann M; Allen JM; Leelarathna L; Hartnell S; Wilinska ME; Acerini CL; Dellweg S; Benesch C; Heinemann L; Mader JK; Holzer M; Kojzar H; Exall J; Yong J; Pichierri J; Barnard KD; Kollman C; Cheng P; Hindmarsh PC; Campbell FM; Arnolds S; Pieber TR; Evans ML; Dunger DB; Hovorka R
    N Engl J Med; 2015 Nov; 373(22):2129-2140. PubMed ID: 26379095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
    Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.
    Oskarsson P; Antuna R; Geelhoed-Duijvestijn P; Krӧger J; Weitgasser R; Bolinder J
    Diabetologia; 2018 Mar; 61(3):539-550. PubMed ID: 29273897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Automated insulin dosing guidance to optimise insulin management in patients with type 2 diabetes: a multicentre, randomised controlled trial.
    Bergenstal RM; Johnson M; Passi R; Bhargava A; Young N; Kruger DF; Bashan E; Bisgaier SG; Isaman DJM; Hodish I
    Lancet; 2019 Mar; 393(10176):1138-1148. PubMed ID: 30808512
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial.
    McAuley SA; Trawley S; Vogrin S; Ward GM; Fourlanos S; Grills CA; Lee MH; Alipoor AM; O'Neal DN; O'Regan NA; Sundararajan V; Colman PG; MacIsaac RJ
    Diabetes Care; 2022 Feb; 45(2):381-390. PubMed ID: 34844995
    [TBL] [Abstract][Full Text] [Related]  

  • 37. One-year real-world performance of the DBLG1 closed-loop system: Data from 3706 adult users with type 1 diabetes in Germany.
    Benhamou PY; Adenis A; Lebbad H; Tourki Y; Heredia MB; Gehr B; Franc S; Charpentier G
    Diabetes Obes Metab; 2023 Jun; 25(6):1607-1613. PubMed ID: 36751978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial.
    Visser MM; Charleer S; Fieuws S; De Block C; Hilbrands R; Van Huffel L; Maes T; Vanhaverbeke G; Dirinck E; Myngheer N; Vercammen C; Nobels F; Keymeulen B; Mathieu C; Gillard P
    Lancet; 2021 Jun; 397(10291):2275-2283. PubMed ID: 34089660
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial.
    Reznik Y; Cohen O; Aronson R; Conget I; Runzis S; Castaneda J; Lee SW;
    Lancet; 2014 Oct; 384(9950):1265-72. PubMed ID: 24998009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fully Closed-Loop Glucose Control Compared With Insulin Pump Therapy With Continuous Glucose Monitoring in Adults With Type 1 Diabetes and Suboptimal Glycemic Control: A Single-Center, Randomized, Crossover Study.
    Boughton CK; Hartnell S; Lakshman R; Nwokolo M; Wilinska ME; Ware J; Allen JM; Evans ML; Hovorka R
    Diabetes Care; 2023 Nov; 46(11):1916-1922. PubMed ID: 37616583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.